{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:28:23Z","timestamp":1761017303791,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GBJ Pharma, Ltd., Warsaw, Poland."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40123-020-00256-8","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T19:02:38Z","timestamp":1588878158000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Peripheral Latanoprost Administration Lowers\nIntraocular Pressure in the Wistar Rat"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-6836","authenticated-orcid":false,"given":"Maciej","family":"\u015awi\u0105tkiewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0158-7646","authenticated-orcid":false,"given":"Marlena","family":"We\u0142niak-Kami\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-3608","authenticated-orcid":false,"given":"Micha\u0142","family":"Fiedorowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Kami\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3321-2723","authenticated-orcid":false,"given":"Robert","family":"Rejdak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6983-7947","authenticated-orcid":false,"given":"Pawe\u0142","family":"Grieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"256_CR1","doi-asserted-by":"crossref","unstructured":"Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost\nfor glaucoma since its launch. Expert Opin Pharmacother.\n2012;13:723\u201345.","DOI":"10.1517\/14656566.2012.662219"},{"key":"256_CR2","unstructured":"WHO Essential Medicines and Health Products Department. World Health\nOrganization model list of essential medicines, 21st edn. World Health Organization.\n2019. https:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/. Accessed 10 Mar 2020."},{"key":"256_CR3","doi-asserted-by":"crossref","unstructured":"Klimko PG, Sharif NA. Discovery, characterization and clinical utility\nof prostaglandin agonists for the treatment of glaucoma. Br J Pharmacol. 2019;176:\n1051\u20138.\u00a0","DOI":"10.1111\/bph.14327"},{"key":"256_CR4","unstructured":"Pfizer Inc.\/Pfizer Ltd. Pfizer material safety data sheet. Latanoprost\nsolution. Pfizer Inc. 2009. https:\/\/www.pfizer.com\/sites\/default\/files\/products\/material_safety_data\/LATANOPROST%20SOLUTION.pdf.\u00a0Accessed 08 Mar 2020."},{"key":"256_CR5","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1097\/IJG.0000000000001055","volume":"27","author":"J Aspberg","year":"2018","unstructured":"Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with\nocular hypotensive treatment in patients with glaucoma or ocular hypertension an\nevidence-based review. Ophthalmology. 2005;112:953\u201361.","journal-title":"J Glaucoma"},{"key":"256_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.therap.2016.02.033","volume":"71","author":"M Belhassen","year":"2016","unstructured":"Belhassen M, Laforest L, Licaj I, Van Ganse E. Early adherence to\nanti-glaucoma therapy: an observational study. Therapie.\n2016;71:491\u20139.\u00a0","journal-title":"Therapie"},{"key":"256_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/APO.0000000000000122","volume":"4","author":"S Chen","year":"2015","unstructured":"Zarnowski T, Wyszynska A, Rekas M. Comparison of self-reported and\nobjective adherence to antiglaucoma medications. J Ocul Pharmacol Ther.\n2016;32:403\u20134.\u00a0","journal-title":"Asia Pac J Ophthalmol"},{"key":"256_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/14656566.2012.662219","volume":"13","author":"M Digiuni","year":"2012","unstructured":"Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and\npersistence across 6 chronic medication classes. J Manag Care Pharm.\n2009;15:728\u201340.\u00a0","journal-title":"Expert Opin Pharmacother"},{"key":"256_CR9","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s00417-003-0835-1","volume":"242","author":"S Dinslage","year":"2004","unstructured":"Sjoquist B, Basu S, Byding P, Bergh K, Stjernschantz J. The\npharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab\nDispos. 1998;26:745\u201354.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"256_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjo.78.1.38","volume":"78","author":"CN Dunham","year":"1994","unstructured":"Dinslage S, Hueber A, Diestelhorst M, Krieglstein G. The influence of\nlatanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a\ndouble-masked placebo-controlled clinical study. Graefes Arch Clin Exp Ophthalmol.\n2004;242:654\u201360.\u00a0","journal-title":"Br J Ophthalmol"},{"key":"256_CR11","unstructured":"Sandoz Canada Inc. Product monograph. PrSandoz latanoprost. Latanoprost\nophthalmic solution, 50 mcg\/mL. Sandoz Canada Inc. 2017. https:\/\/www.sandoz.ca\/sites\/www.sandoz.ca\/files\/Sandoz%20Latanoprost%20Product%20Monograph.pdf.\u00a0Accessed 05 Mar 2020."},{"key":"256_CR12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/bph.14327","volume":"176","author":"PG Klimko","year":"2019","unstructured":"Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of\nlatanoprost in humans. Surv Ophthalmol. 2002;47(Suppl 1):S6\u201312.\u00a0","journal-title":"Br J Pharmacol"},{"key":"256_CR13","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1517\/14656566.2013.813482","volume":"14","author":"AG Konstas","year":"2013","unstructured":"Dunham CN, Spaide RF, Dunham G. The contralateral reduction of\nintraocular pressure by timolol. Br J Ophthalmol. 1994;78:38\u201340.\u00a0","journal-title":"Expert Opin Pharmacother"},{"key":"256_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","volume":"132","author":"F Kratz","year":"2008","unstructured":"Sadiq SA, Vernon SA. Sublingual timolol\u2014an alternative to topical\nmedication in glaucoma? Br J Ophthalmol. 1996;80:532\u20135.","journal-title":"J Control Release"},{"key":"256_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ajo.2016.11.020","volume":"175","author":"RA Lewis","year":"2017","unstructured":"Quaranta L, Pasquini L, Cassamali M, Hauranieh N, Gandolfo E, Quaranta\nCA. Ocular hypotensive effect of sublingual administration of timolol. Int\nOphthalmol. 1996;20:49\u201351.","journal-title":"Am J Ophthalmol"},{"key":"256_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0079-6123(08)01121-7","volume":"173","author":"JC Morrison","year":"2008","unstructured":"Konstas AG, Mocan MC, Katsanos A, Voudouragkaki IC, Irkec M.\nLatanoprost\/timolol fixed combination for the treatment of glaucoma. Expert Opin\nPharmacother. 2013;14:1815\u201327.\u00a0","journal-title":"Prog Brain Res"},{"key":"256_CR17","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","volume":"112","author":"CM Olthoff","year":"2005","unstructured":"Suzuki G, Kunikane E, Shinno K, Kozai S, Kurata M, Kawamura A. Ocular\nand systemic pharmacokinetics of brimonidine and timolol after topical administration\nin rabbits: comparison between fixed-combination and single drugs. Ophthalmol Ther.\n2020;9:115\u201325.\u00a0","journal-title":"Ophthalmology"},{"key":"256_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/IJG.0b013e3181405d4f","volume":"16","author":"IH Pang","year":"2007","unstructured":"Pease ME, Cone FE, Gelman S, Son JL, Quigley HA. Calibration of the\nTonoLab tonometer in mice with spontaneous or experimental glaucoma. Investig\nOphthalmol Vis Sci. 2011;52:858\u201364.","journal-title":"J Glaucoma"},{"key":"256_CR19","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1167\/iovs.10-5556","volume":"52","author":"ME Pease","year":"2011","unstructured":"Fiedorowicz M, Orzel J, Kossowski B, et al. Anterograde transport in\naxons of the retinal ganglion cells and its relationship to the intraocular pressure\nduring aging in mice with hereditary pigmentary glaucoma. Curr Eye Res.\n2018;43:539\u201346.\u00a0","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"256_CR20","first-page":"49","volume":"20","author":"L Quaranta","year":"1996","unstructured":"Aspberg J, Heijl A, Johannesson G, Linden C, Andersson-Geimer S,\nBengtsson B. Intraocular pressure lowering effect of latanoprost as first-line\ntreatment for glaucoma. J Glaucoma. 2018;27: 976\u201380.","journal-title":"Int Ophthalmol"},{"key":"256_CR21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1136\/bjo.80.6.532","volume":"80","author":"SA Sadiq","year":"1996","unstructured":"Lewis RA, Christie WC, Day DG, et al. Bimatoprost sustained-release\nimplants for glaucoma therapy: 6-month results from a phase I\/II clinical trial. Am J\nOphthalmol. 2017;175:137\u201347.\u00a0","journal-title":"Br J Ophthalmol"},{"key":"256_CR22","first-page":"745","volume":"26","author":"B Sjoquist","year":"1998","unstructured":"Aref AA. Sustained drug delivery for glaucoma: current data and future\ntrends. Curr Opin Ophthalmol. 2017;28:169\u201374.","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 1","key":"256_CR23","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S0039-6257(02)00302-8","volume":"47","author":"B Sjoquist","year":"2002","unstructured":"Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates\nand nanoparticles. J Control Release. 2008;132:171\u201383.","journal-title":"Surv Ophthalmol"},{"key":"256_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40123-020-00229-x","volume":"9","author":"G Suzuki","year":"2020","unstructured":"Zhivkova ZD. Studies on drug-human serum albumin binding: the current\nstate of the matter. Curr Pharm Des. 2015;21:1817\u201330.","journal-title":"Ophthalmol Ther"},{"key":"256_CR25","doi-asserted-by":"crossref","first-page":"728","DOI":"10.18553\/jmcp.2009.15.9.728","volume":"15","author":"J Yeaw","year":"2009","unstructured":"Pang IH, Clark AF. Rodent models for glaucoma retinopathy and optic\nneuropathy. J Glaucoma. 2007;16:483\u2013505.","journal-title":"J Manag Care Pharm"},{"key":"256_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/jop.2016.0052","volume":"32","author":"T Zarnowski","year":"2016","unstructured":"Chen S, Zhang X. The rodent model of glaucoma and its implications.\nAsia Pac J Ophthalmol. 2015;4: 236\u201341.\u00a0","journal-title":"J Ocul Pharmacol Ther"},{"key":"256_CR27","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2174\/1381612821666150302113710","volume":"21","author":"ZD Zhivkova","year":"2015","unstructured":"Morrison JC, Johnson E, Cepurna WO. Rat models for glaucoma research.\nProg Brain Res. 2008;173: 285\u2013301.\u00a0","journal-title":"Curr Pharm Des"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-020-00256-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-020-00256-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-020-00256-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T23:09:40Z","timestamp":1628118580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-020-00256-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1007\/s40123-020-00256-8","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"type":"print","value":"2193-8245"},{"type":"electronic","value":"2193-6528"}],"subject":[],"published":{"date-parts":[[2020,8,5]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}